You are here:
Supplement Manufacturing — Pharmaceutical Grade
Last Updated:February 28, 2026
About This Investor
JP-B-201
With roots in Japan, they are currently screening targets across Indonesia, Malaysia, India. Sales of over 1 billion yen Stable operating profit Minority investment desired. Key target profile: Pharmaceutical (supplement) manufacturing and sales. The primary M&A purpose is Expand existing businesses overseas. Budget guidance is $6.54M – $13.1M. Reach out to us to share a…
Pharmaceutical Manufacturing (Supplements)
India, Indonesia, Malaysia
Overseas Expansion
$6.54M - $13.1M
Minority preferred | Revenue ≥ USD 6.5M | Stable op profit
Request Full Investor Profile
Similar Investors
JP-B-31
Investment thesis: Based in Japan, this investor is open to
Diversified / Conglomerate
Asia
Growth Investment
$19.6M - $65.4M
Majority | Revenue ≥ USD 32.7M
JP-B-488
Geographic and deal conditions are important for this mandate: Singapore,
Food Manufacturing
Singapore, Thailand
Sales Expansion
$3.27M - $19.6M
Minority / Majority / 100%
JP-B-325
Key target profile: We own a network of forwarding and
Logistics Real Estate
Europe, India, Indonesia, Malaysia, Mexico, North America, Singapore, Thailand, Vietnam
Strategic Expansion
$6.54M - $130.8M
Majority